Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669949 · ClinicalTrials.gov registry record
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
A clinical trial of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS), sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 28
- Enrollment target
- 1
- Study location
NCT06669949: Recruiting study of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS), sponsored by University of California, San Francisco.
NCT06669949 is a study of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06669949, a study of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS), is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective longitudinal natural history study with a retrospective cross-sectional arm aimed at determining the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS), a recently recognized inborn error of metabolism. The central hypothesis is that age of onset, other disease features, and disease biomarkers will be predictive of quality of life (QOL) and survival in SPLIS patients.
Primary Outcome
The primary outcome of this study is survival (age at death).
Conditions Studied
Interventions
- OTHER no intervention
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-22 |
| Est. Completion | 2030-12-31 |
What NCT06669949 shows while recruiting
NCT06669949 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 1 condition, with Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS) appearing as the primary indexed condition, and to 1 intervention - of which no intervention is the first listed.
NCT06669949 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06669949 about?
NCT06669949 is a clinical study titled "Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)". This is a prospective longitudinal natural history study with a retrospective cross-sectional arm aimed at determining the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS), a recently recognized inborn error of metabolism. The central hypothesis is that age of onset, oth...
What is the current status of trial NCT06669949?
This trial is currently recruiting. The enrollment target is 28 participants. The study started on 2025-04-22. Estimated completion is 2030-12-31.
What conditions does trial NCT06669949 study?
This clinical trial studies the following conditions: Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS).
What interventions are being tested in trial NCT06669949?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT06669949?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06669949 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI